What would NOT be a consequence of a change in FDA policy?

The choice indicating that the FDA will comment on compliance or enforcement approach if requested is the correct answer because it reflects a reactive rather than proactive aspect of FDA policy. This means that the FDA's willingness to comment on compliance or enforcement does not inherently result from a change in policy but rather is a function of the agency's existing practices and obligations.

In contrast, a change in FDA policy can lead to various significant outcomes. For instance, increased speed of drug approvals typically indicates that the agency is adapting its review processes or implementing new initiatives aimed at facilitating faster access to essential medications. Enhanced regulatory compliance monitoring could arise from revised policies that require more rigorous oversight of clinical trials and post-marketing surveillance. Additionally, new guidelines for the industry could stem from changes in FDA policy that aim to clarify expectations and streamline processes for drug development and evaluation. These options reflect direct consequences of policy changes, leading to alterations in the regulatory landscape and industry practices.